IPQ Inside the global regulatory dialogue

FDA Preapproval Inspections Enhanced by New Guidance, Reviewer Participation

Nov 15th, 2010

Please Log in to print the full article

Increased reviewer engagement with investigators is impacting the preapproval inspection (PAI) process and helping FDA address the growing complexity of products and processes it faces in reviewing new drug applications (NDAs) and their supplements (sNDAs).......

You must be a paid subscriber to continue reading this article. If you are a paid subscriber, please Log in. If you are not a paid subscriber, please subscribe now.

©2021 IPQ Publications